Logo image of BTLS.BR

BIOTALYS NV (BTLS.BR) Stock Fundamental Analysis

EBR:BTLS - Euronext Brussels - BE0974386188 - Common Stock - Currency: EUR

5.3  +0.02 (+0.38%)

Fundamental Rating

2

Overall BTLS gets a fundamental rating of 2 out of 10. We evaluated BTLS against 67 industry peers in the Chemicals industry. The financial health of BTLS is average, but there are quite some concerns on its profitability. BTLS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BTLS has reported negative net income.
BTLS had a negative operating cash flow in the past year.
In the past 5 years BTLS always reported negative net income.
In the past 5 years BTLS always reported negative operating cash flow.
BTLS.BR Yearly Net Income VS EBIT VS OCF VS FCFBTLS.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

With a Return On Assets value of -35.89%, BTLS is not doing good in the industry: 89.55% of the companies in the same industry are doing better.
BTLS has a Return On Equity of -47.77%. This is amonst the worse of the industry: BTLS underperforms 83.58% of its industry peers.
Industry RankSector Rank
ROA -35.89%
ROE -47.77%
ROIC N/A
ROA(3y)-45.95%
ROA(5y)-38.32%
ROE(3y)-62.54%
ROE(5y)-51.65%
ROIC(3y)N/A
ROIC(5y)N/A
BTLS.BR Yearly ROA, ROE, ROICBTLS.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BTLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BTLS.BR Yearly Profit, Operating, Gross MarginsBTLS.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

BTLS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BTLS has more shares outstanding
Compared to 1 year ago, BTLS has an improved debt to assets ratio.
BTLS.BR Yearly Shares OutstandingBTLS.BR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
BTLS.BR Yearly Total Debt VS Total AssetsBTLS.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

An Altman-Z score of 12.20 indicates that BTLS is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 12.20, BTLS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
BTLS has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.13, BTLS belongs to the top of the industry, outperforming 80.60% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Altman-Z 12.2
ROIC/WACCN/A
WACCN/A
BTLS.BR Yearly LT Debt VS Equity VS FCFBTLS.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

BTLS has a Current Ratio of 5.50. This indicates that BTLS is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 5.50, BTLS belongs to the best of the industry, outperforming 97.01% of the companies in the same industry.
A Quick Ratio of 5.50 indicates that BTLS has no problem at all paying its short term obligations.
BTLS's Quick ratio of 5.50 is amongst the best of the industry. BTLS outperforms 98.51% of its industry peers.
Industry RankSector Rank
Current Ratio 5.5
Quick Ratio 5.5
BTLS.BR Yearly Current Assets VS Current LiabilitesBTLS.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

3

3. Growth

3.1 Past

BTLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.92%, which is quite impressive.
EPS 1Y (TTM)38.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

BTLS is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -62.35% yearly.
BTLS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.08% yearly.
EPS Next Y-111.84%
EPS Next 2Y-46.45%
EPS Next 3Y-62.35%
EPS Next 5YN/A
Revenue Next Year-60%
Revenue Next 2Y-29.29%
Revenue Next 3Y22.08%
Revenue Next 5YN/A

3.3 Evolution

BTLS.BR Yearly Revenue VS EstimatesBTLS.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2023 2024 2025 2026 2027 2M 4M 6M 8M
BTLS.BR Yearly EPS VS EstimatesBTLS.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BTLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BTLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BTLS.BR Price Earnings VS Forward Price EarningsBTLS.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BTLS.BR Per share dataBTLS.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A cheap valuation may be justified as BTLS's earnings are expected to decrease with -62.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-46.45%
EPS Next 3Y-62.35%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BTLS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOTALYS NV

EBR:BTLS (6/27/2025, 11:03:25 AM)

5.3

+0.02 (+0.38%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners23.43%
Inst Owner ChangeN/A
Ins Owners4.85%
Ins Owner ChangeN/A
Market Cap198.59M
Analysts87.5
Price Target7.24 (36.6%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.08%
PT rev (3m)10.08%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-0.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.19
P/tB 7.35
EV/EBITDA N/A
EPS(TTM)-0.4
EYN/A
EPS(NY)-0.82
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0
BVpS0.74
TBVpS0.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.89%
ROE -47.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.95%
ROA(5y)-38.32%
ROE(3y)-62.54%
ROE(5y)-51.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.55%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.5
Quick Ratio 5.5
Altman-Z 12.2
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)25.97%
Cap/Depr(5y)109.26%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.42%
EPS Next Y-111.84%
EPS Next 2Y-46.45%
EPS Next 3Y-62.35%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-60%
Revenue Next 2Y-29.29%
Revenue Next 3Y22.08%
Revenue Next 5YN/A
EBIT growth 1Y35.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-11.54%
EBIT Next 3Y-39.01%
EBIT Next 5YN/A
FCF growth 1Y31.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.8%
OCF growth 3YN/A
OCF growth 5YN/A